Virometix AG

Virometix is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a proprietary modular and fully synthetic nanoparticle technology platform, our vaccines are purposefully designed, are safe, and of low cost and scalable production. Our lead indication for Respiratory Syncytial Virus (RSV) infections targets a high unmet need.